- Markets
- Healthcare
- JENBURPH
JENBURPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Jenburkt Pharma hits record high on Q2 profit rise
** Shares of Jenburkt Pharmaceuticals JENA.BO rise as much as 17.3% to a record high of 1,275 rupees
** JENA eyes its fifth straight session of gains
** The pharma co posted a 31% rise in Q2 PAT and revenue from ops increased ~8% Y/Y
** More than 23,000 shares change hands, 13.1x its 30-day avg; eyes most active volumes since Jan. 6, 2023
** Stock up 83% so far this year
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Jenburkt Pharmaceuticals JENA.BO rise as much as 17.3% to a record high of 1,275 rupees
** JENA eyes its fifth straight session of gains
** The pharma co posted a 31% rise in Q2 PAT and revenue from ops increased ~8% Y/Y
** More than 23,000 shares change hands, 13.1x its 30-day avg; eyes most active volumes since Jan. 6, 2023
** Stock up 83% so far this year
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
India's Jenburkt Pharmaceuticals March-Quarter PAT Rises
May 23 (Reuters) - Jenburkt Pharmaceuticals Ltd JENA.BO:
MARCH-QUARTER PAT 63.5 MILLION RUPEES VERSUS PROFIT 34.5 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 352 MILLION RUPEES VERSUS 282.9 MILLION RUPEES
DIVIDEND 14.40 RUPEES PER SHARE
Source text for Eikon: ID:nBSE2JMN0Z
Further company coverage: JENA.BO
(([email protected];))
May 23 (Reuters) - Jenburkt Pharmaceuticals Ltd JENA.BO:
MARCH-QUARTER PAT 63.5 MILLION RUPEES VERSUS PROFIT 34.5 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 352 MILLION RUPEES VERSUS 282.9 MILLION RUPEES
DIVIDEND 14.40 RUPEES PER SHARE
Source text for Eikon: ID:nBSE2JMN0Z
Further company coverage: JENA.BO
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Jenburkt Pharma do?
Jenburkt Pharmaceuticals Limited, based in India, specializes in manufacturing and marketing pharmaceutical formulations and healthcare products under two divisions: consumer and pharmaceutical. They have a diverse product portfolio with approximately 50 brands promoted through doctors.
Who are the competitors of Jenburkt Pharma?
Jenburkt Pharma major competitors are Medico Remedies, Albert David, Venus Remedies, Ind-Swift Lab., Zim Laboratories, Brooks Laboratories, Lyka Labs. Market Cap of Jenburkt Pharma is ₹489 Crs. While the median market cap of its peers are ₹450 Crs.
Is Jenburkt Pharma financially stable compared to its competitors?
Jenburkt Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Jenburkt Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Jenburkt Pharma latest dividend payout ratio is 25.99% and 3yr average dividend payout ratio is 25.51%
How has Jenburkt Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Jenburkt Pharma balance sheet?
Balance sheet of Jenburkt Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Jenburkt Pharma improving?
Yes, profit is increasing. The profit of Jenburkt Pharma is ₹31.41 Crs for TTM, ₹25.98 Crs for Mar 2024 and ₹24.61 Crs for Mar 2023.
Is the debt of Jenburkt Pharma increasing or decreasing?
Yes, The debt of Jenburkt Pharma is increasing. Latest debt of Jenburkt Pharma is -₹77.69 Crs as of Sep-24. This is greater than Mar-24 when it was -₹158.32 Crs.
Is Jenburkt Pharma stock expensive?
Yes, Jenburkt Pharma is expensive. Latest PE of Jenburkt Pharma is 15.57, while 3 year average PE is 13.13. Also latest EV/EBITDA of Jenburkt Pharma is 10.44 while 3yr average is 8.41.
Has the share price of Jenburkt Pharma grown faster than its competition?
Jenburkt Pharma has given lower returns compared to its competitors. Jenburkt Pharma has grown at ~14.83% over the last 6yrs while peers have grown at a median rate of 20.44%
Is the promoter bullish about Jenburkt Pharma?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Jenburkt Pharma is 46.68% and last quarter promoter holding is 46.69%
Are mutual funds buying/selling Jenburkt Pharma?
There is Insufficient data to gauge this.